QCM
MYGN icon

Quantinno Capital Management’s Myriad Genetics MYGN Stock Holding History

Quantinno Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
59,566
-31,056
-34% -$141K ﹤0.01% 3161
2026
Q1 		$408K Buy
90,622
+19,179
+27% +$99.9K ﹤0.01% 2849
2025
Q4 		$439K Buy
71,443
+45,251
+173% +$328K ﹤0.01% 2549
2025
Q3 		$189K Buy
26,192
+5,587
+27% +$33.2K ﹤0.01% 2777
2025
Q2 		$109K Buy
+20,605
New +$122K ﹤0.01% 2497

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quantinno Capital Management's MYGN Position: Q2 2026 in Review

Quantinno Capital Management reduced its Myriad Genetics (MYGN) stake by 34% in Q2 2026, selling an estimated $141K and leaving 59,566 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3161.

Quantinno Capital Management first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $439K in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Quantinno Capital Management held 59,566 shares of Myriad Genetics worth $340K as of Q2 2026.
  • Quantinno Capital Management sold 31,056 Myriad Genetics shares in Q2 2026, an estimated $141K.
  • Myriad Genetics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3161 holding.
  • Quantinno Capital Management first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • Quantinno Capital Management's Myriad Genetics position peaked at $439K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.